Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)

Hepatology

Volumn 62, Issue 3, 2015, Pages 737-750

  Trinchet, Jean Claude ^a,al   Bourcier, Valérie ^a,al   Chaffaut, Cendrine ^b   Ait Ahmed, Mohand ^a,al   Allam, Setty ^c   Marcellin, Patrick ^d   Guyader, Dominique ^e   Pol, Stanislas ^f   Larrey, Dominique ^g   De Lédinghen, Victor ^h   Ouzan, Denis ⁱ   Zoulim, Fabien ^j   Roulot, Dominique ^k   Tran, Albert ^l   Bronowicki, Jean Pierre ^m   Zarski, Jean Pierre ⁿ   Goria, Odile ^o   Calès, Paul ^p   Péron, Jean Marie ^q   Alric, Laurent ^r   Bourlière, Marc ^s   Mathurin, Philippe ^t   Blanc, Jean Frédéric ^u   Abergel, Armand ^v   Serfaty, Lawrence ^w   Mallat, Ariane ^x   Grangé, Jean Didier ^y   Buffet, Catherine ^z   Bacq, Yannick ^aa   Wartelle, Claire ^ab   Dao, Thông ^ac   Benhamou, Yves ^ad   Pilette, Christophe ^ae   Silvain, Christine ^af   Christidis, Christos ^ag   Capron, Dominique ^ah   Thiefin, Gérard ^ai   Hillaire, Sophie ^aj   Di Martino, Vincent ^ak   Nahon, Pierre ^a,al   Chevret, Sylvie ^b   more..

^a HÔPITAL JEAN VERDIER   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c Unit for Basic and Clinical Research on Viral Hepatitis   (France)

^d BEAUJON HOSPITAL   (France)

^e PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^f Service de Médecine Interne Pôle Digestif UMR 152 ^*  (France)

^g HÔPITAL SAINT ELOI   (France)

^h HAUT LÉVÊQUE HOSPITAL   (France)

ⁱ INSTITUT ARNAULT TZANCK   (France)

^j HÔTEL DIEU   (France)

^k AVICENNE HOSPITAL   (France)

^l UNIVERSITY HOSPITAL OF NICE   (France)

^m CHU NANCY BRABOIS   (France)

ⁿ HÔPITAL MICHALLON   (France)

^o HÔPITAL CHARLES NICOLLE   (France)

^p ANGERS UNIVERSITY HOSPITAL   (France)

^q CHU PURPAN   (France)

^r TOULOUSE UNIVERSITY HOSPITAL   (France)

^s HÔPITAL SAINT JOSEPH   (France)

^t LILLE UNIVERSITY HOSPITAL   (France)

^u HÔPITAL SAINT ANDRÉ   (France)

^v HÔTEL DIEU   (France)

^w HÔPITAL SAINT ANTOINE   (France)

^x HENRI MONDOR HOSPITAL   (France)

^y HÔPITAL TENON   (France)

^z BICÊTRE HOSPITAL   (France)

^aa SERVICE DE DERMATOLOGIE   (France)

^ab Hôpital d'Aix en Provence   (France)

^ac CHU CÔTE DE NACRE   (France)

^ad ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^ae CHU du Mans   (France)

^af POITIERS UNIVERSITY HOSPITAL   (France)

^ag INSTITUT MUTUALISTE MONTSOURIS   (France)

^ah AMIENS UNIVERSITY HOSPITAL   (France)

^ai SERVICE DE DERMATOLOGIE   (France)

^aj FOCH HOSPITAL   (France)

^ak UNIVERSITÉ PARIS 13   (France)

^al Université Paris 13   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BACTERIAL INFECTION; BILE DUCT CARCINOMA; CANCER INCIDENCE; CARDIOVASCULAR DISEASE; CHILD PUGH SCORE; COMORBIDITY; COMPENSATED LIVER CIRRHOSIS; COMPENSATED VIRAL CIRRHOSIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; FEMALE; FOLLOW UP; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LIVER NODULE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL; VIRAL CLEARANCE; VIRUS REPLICATION; ANALYSIS OF VARIANCE; CAUSE OF DEATH; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; COMPLICATION; DISEASE COURSE; FRANCE; HEPATITIS B; HEPATITIS C; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TUMOR; LONGITUDINAL STUDY; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; VIROLOGY;

ADULT; ANALYSIS OF VARIANCE; CARCINOMA, HEPATOCELLULAR; CAUSE OF DEATH; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FRANCE; HEPATITIS B; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER FAILURE; LIVER NEOPLASMS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 84939651262     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27743     Document Type: Article

References (28)

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264-1273.e1.
2. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35-S50.
3. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006;43:1303-1310.
4. Leon DA, McCambridge J. Liver cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data. Lancet 2006;367:52-56.
5. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397-417.
6. Jepsen P, Vilstrup H, Lash TL. Development and validation of a comorbidity scoring system for patients with cirrhosis. Gastroenterology 2014;146:147-156; quiz, e115-e146.
7. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013;58:98-107.
8. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-2593.
9. Wong GL, Chan HL, Mak CH, Lee SK, Ip ZM, Lam AT, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013;58:1537-1547.
10. Jepsen P, Vilstrup H, Andersen PK. The clinical course of cirrhosis: the importance of multi-state models and competing risks analysis. Hepatology 2014 Nov 5. doi: 10.1002/hep.27598. [Epub ahead of print].
11. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005;366:1059-1062.
12. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
13. de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010;53:762-768.
14. Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, Stadlbauer V, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol 2014;60:1310-1324.
15. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
16. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012;56(Suppl 1):S88-S100.
17. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
18. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
19. Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011;54:1987-1997.
20. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004;10(2 Suppl 1):S115-S120.
21. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007;46:1350-1356.
22. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531.
23. Bruno S, Shiffman ML, Roberts SK, Gane EJ, Messinger D, Hadziyannis SJ, Marcellin P. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010;51:388-397.
24. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-1982.
25. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014;11:e1001624.
26. Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010;52:132-141.
27. Ulahannan SV, Duffy AG, McNeel TS, Kish JK, Dickie LA, Rahma OE, et al. Earlier presentation and application of curative treatments in hepatocellular carcinoma. Hepatology 2014;60:1637-1644.
28. Turati F, Edefonti V, Talamini R, Ferraroni M, Malvezzi M, Bravi F, et al. Family history of liver cancer and hepatocellular carcinoma. Hepatology 2012;55:1416-1425.